MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
Verona Pharma plc ROE Ratio 2011-2026 | VRNA
Annual ROE Ratio Verona Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -84.78 | -21.81 | -29.81 | -37.55 | -35.24 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.81 | -84.78 | -41.84 |
Quarterly ROE Ratio Verona Pharma plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -68.76 | -115.14 | -86.48 | -92.06 | -64.71 | -25.84 | -14.85 | -21.44 | -22.45 | -35.25 | -42.28 | -35.71 | -22.55 | -20.82 | -20.07 | -30.31 | -47.12 | -37.72 | -21.81 | -21.81 | -11.57 | -6.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -6.68 | -115.14 | -39.34 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
-311.44 | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-41.09 | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
36.21 | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Immuron Limited
IMRN
|
-12.31 | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
24.9 | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
-195.26 | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
23.12 | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
286.68 | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
9.59 | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
16.8 | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 12.42 | - | $ 1.65 B | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.49 | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
-154.03 | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |